Sena L, Kumar R, Sanin D, Thompson E, Rosen D, Dalrymple S, et al. Androgen receptor activity in prostate cancer dictates efficacy of bipolar androgen therapy through MYC. J Clin Invest. 2022;132: pubmed publisher

Nguyen T, Shang E, Shu C, Kim S, Mela A, Humala N, et al. Aurora kinase A inhibition reverses the Warburg effect and elicits unique metabolic vulnerabilities in glioblastoma. Nat Commun. 2021;12:5203 pubmed publisher

Cho S, Lee G, Pickering B, Jang C, Park J, He L, et al. mTORC1 promotes cell growth via m6A-dependent mRNA degradation. Mol Cell. 2021;81:2064-2075.e8 pubmed publisher

Lee J, Wu Y, Harada B, Li Y, Zhao J, He C, et al. N6 -methyladenosine modification of lncRNA Pvt1 governs epidermal stemness. EMBO J. 2021;40:e106276 pubmed publisher

Guo Y, Ye Q, Deng P, Cao Y, He D, Zhou Z, et al. Spermine synthase and MYC cooperate to maintain colorectal cancer cell survival by repressing Bim expression. Nat Commun. 2020;11:3243 pubmed publisher

Morel M, Shah K, Long W. The F-box protein FBXL16 up-regulates the stability of C-MYC oncoprotein by antagonizing the activity of the F-box protein FBW7. J Biol Chem. 2020;295:7970-7980 pubmed publisher

Weng H, Huang H, Wu H, Qin X, Zhao B, Dong L, et al. METTL14 Inhibits Hematopoietic Stem/Progenitor Differentiation and Promotes Leukemogenesis via mRNA m6A Modification. Cell Stem Cell. 2018;22:191-205.e9 pubmed publisher

Mukhopadhyay A, Hanold L, Thayele Purayil H, Gisemba S, Senadheera S, Aldrich J. Macrocyclic peptides decrease c-Myc protein levels and reduce prostate cancer cell growth. Cancer Biol Ther. 2017;18:571-583 pubmed publisher

Vo B, Wolf E, Kawauchi D, Gebhardt A, Rehg J, Finkelstein D, et al. The Interaction of Myc with Miz1 Defines Medulloblastoma Subgroup Identity. Cancer Cell. 2016;29:5-16 pubmed publisher